nortriptyline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antidepressants, dibenzo[a,d]cycloheptane or cyclopheptene derivatives 1971 72-69-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nortryptyline
  • nortriptyline
  • demethylamitriptylin
  • desitriptilina
  • desmethylamitriptyline
  • noramitriptyline
  • nortriptyline hydrochloride
  • nortriptyline HCl
A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
  • Molecular weight: 263.38
  • Formula: C19H21N
  • CLOGP: 4.31
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -5.48
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
75 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.34 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.12 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 6, 1964 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 355.92 11.97 123 32378 4084 53312481
Completed suicide 302.82 11.97 396 32105 137805 53178760
Food allergy 285.65 11.97 126 32375 8092 53308473
Coeliac disease 278.28 11.97 126 32375 8609 53307956
Pneumonia aspiration 270.88 11.97 199 32302 34102 53282463
Immunodeficiency 216.84 11.97 127 32374 14840 53301725
Bursitis 187.77 11.97 135 32366 22357 53294208
Toxicity to various agents 186.40 11.97 412 32089 219186 53097379
Coma 180.54 11.97 205 32296 61578 53254987
Gastrooesophageal reflux disease 174.80 11.97 233 32268 82430 53234135
Presbyacusis 134.25 11.97 55 32446 2937 53313628
Pleural thickening 133.27 11.97 53 32448 2619 53313946
Somnolence 131.35 11.97 305 32196 167429 53149136
Pleural fibrosis 130.81 11.97 57 32444 3551 53313014
Blood magnesium increased 129.22 11.97 54 32447 3033 53313532
Osteopenia 128.20 11.97 99 32402 18256 53298309
Rash erythematous 125.73 11.97 134 32367 37489 53279076
Deafness neurosensory 121.50 11.97 59 32442 4719 53311846
Drug hypersensitivity 109.00 11.97 382 32119 264860 53051705
Fluid retention 102.35 11.97 145 32356 54256 53262309
Upper respiratory tract infection 98.64 11.97 162 32339 68935 53247630
Epigastric discomfort 93.68 11.97 54 32447 6119 53310446
Asthma 89.45 11.97 202 32299 108770 53207795
Hyperhidrosis 86.89 11.97 186 32315 96607 53219958
Electrocardiogram QRS complex prolonged 83.87 11.97 49 32452 5693 53310872
Bone cyst 81.26 11.97 35 32466 2119 53314446
Overdose 76.77 11.97 189 32312 107547 53209018
Brugada syndrome 76.58 11.97 21 32480 313 53316252
Cyst 67.79 11.97 59 32442 12852 53303713
Rubber sensitivity 65.22 11.97 29 32472 1896 53314669
Osteosclerosis 60.04 11.97 34 32467 3724 53312841
Neovascularisation 58.94 11.97 20 32481 627 53315938
Back pain 58.68 11.97 290 32211 233957 53082608
Blood potassium increased 58.62 11.97 63 32438 17778 53298787
Synovitis 53.53 11.97 3 32498 107890 53208675
Poor venous access 53.21 11.97 46 32455 9929 53306636
Sleep disorder 50.36 11.97 111 32390 58759 53257806
Traumatic coma 49.82 11.97 11 32490 61 53316504
Cardiac arrest 49.29 11.97 147 32354 93520 53223045
Sensitivity to weather change 47.11 11.97 35 32466 6087 53310478
Hepatic enzyme increased 45.97 11.97 175 32326 126020 53190545
Skin lesion 44.58 11.97 70 32431 28659 53287906
Somatic delusion 44.52 11.97 16 32485 596 53315969
Migraine 44.02 11.97 128 32373 80289 53236276
Glossodynia 43.63 11.97 5 32496 100286 53216279
Osteoarthritis 43.30 11.97 117 32384 70369 53246196
Hypersensitivity 43.27 11.97 247 32254 210418 53106147
Constipation 41.65 11.97 234 32267 198178 53118387
Deformity 39.06 11.97 35 32466 7919 53308646
Acute kidney injury 38.94 11.97 59 32442 253809 53062756
Polymyositis 36.66 11.97 19 32482 1745 53314820
Maternal exposure during pregnancy 36.57 11.97 25 32476 155614 53160951
Dry eye 36.51 11.97 70 32431 33574 53282991
Neutropenia 35.53 11.97 27 32474 159158 53157407
Exposure during pregnancy 35.18 11.97 16 32485 124844 53191721
Forced expiratory volume decreased 34.43 11.97 28 32473 5557 53311008
Respiratory arrest 34.23 11.97 68 32433 33472 53283093
Anaemia 33.79 11.97 74 32427 276644 53039921
Febrile neutropenia 33.61 11.97 11 32490 104925 53211640
Erythema 33.50 11.97 186 32315 156783 53159782
Exostosis 33.48 11.97 38 32463 11386 53305179
Systemic lupus erythematosus 32.44 11.97 18 32483 125396 53191169
Alanine aminotransferase abnormal 32.28 11.97 23 32478 3750 53312815
Suspected suicide 31.45 11.97 24 32477 4344 53312221
Spinal stenosis 31.37 11.97 41 32460 14200 53302365
Bone density abnormal 31.10 11.97 21 32480 3141 53313424
Accidental death 31.02 11.97 17 32484 1747 53314818
Swelling 30.68 11.97 43 32458 191062 53125503
Long QT syndrome 30.31 11.97 21 32480 3275 53313290
Paradoxical drug reaction 30.14 11.97 21 32480 3304 53313261
Unmasking of previously unidentified disease 29.64 11.97 13 32488 822 53315743
Occult blood 27.91 11.97 14 32487 1200 53315365
Suicidal ideation 26.35 11.97 89 32412 60422 53256143
Unresponsive to stimuli 26.31 11.97 61 32440 33365 53283200
Pericarditis 26.12 11.97 4 32497 64402 53252163
Cardiac failure 25.78 11.97 10 32491 85834 53230731
Wound 25.37 11.97 12 32489 91545 53225020
Interstitial lung disease 25.30 11.97 3 32498 58619 53257946
Lower respiratory tract infection 25.09 11.97 12 32489 90969 53225596
Atrioventricular block first degree 24.92 11.97 25 32476 6510 53310055
Femoral neck fracture 24.76 11.97 28 32473 8355 53308210
Carpal tunnel syndrome 24.44 11.97 41 32460 17726 53298839
Antidepressant drug level above therapeutic 23.88 11.97 9 32492 384 53316181
Drug ineffective for unapproved indication 23.58 11.97 44 32457 20676 53295889
Pancytopenia 23.58 11.97 13 32488 90915 53225650
Headache 23.56 11.97 458 32043 536363 52780202
Leukopenia 23.00 11.97 8 32493 73455 53243110
Delirium 22.71 11.97 66 32435 41363 53275202
Systolic dysfunction 22.54 11.97 13 32488 1474 53315091
Blood pressure abnormal 22.52 11.97 34 32467 13449 53303116
Depression 22.32 11.97 189 32312 182863 53133702
Hyperaesthesia 22.29 11.97 27 32474 8662 53307903
Paranasal cyst 22.19 11.97 8 32493 301 53316264
Vascular malformation 22.13 11.97 8 32493 303 53316262
Pyrexia 21.79 11.97 150 32351 403043 52913522
Miosis 21.73 11.97 24 32477 6978 53309587
Allodynia 21.64 11.97 10 32491 715 53315850
Electrocardiogram repolarisation abnormality 21.12 11.97 12 32489 1322 53315243
Failed induction of labour 21.02 11.97 8 32493 351 53316214
Alopecia 20.28 11.97 74 32427 234509 53082056
Fibromyalgia 19.34 11.97 65 32436 44010 53272555
Electrocardiogram ST segment elevation 19.26 11.97 17 32484 3772 53312793
Rash 19.03 11.97 177 32324 446014 52870551
Malignant neoplasm progression 18.88 11.97 10 32491 71531 53245034
Thrombocytopenia 18.70 11.97 35 32466 138692 53177873
Abnormal faeces 18.50 11.97 18 32483 4516 53312049
Fatigue 18.41 11.97 578 31923 729928 52586637
Intentional overdose 18.06 11.97 85 32416 67120 53249445
Ventricular tachyarrhythmia 17.96 11.97 5 32496 79 53316486
Postmortem blood drug level increased 17.55 11.97 8 32493 554 53316011
Heart rate increased 17.18 11.97 97 32404 82218 53234347
Sepsis 17.16 11.97 40 32461 146389 53170176
Peripheral swelling 16.53 11.97 67 32434 206041 53110524
Cardio-respiratory arrest 16.29 11.97 75 32426 58683 53257882
Essential tremor 16.06 11.97 9 32492 966 53315599
Septic shock 15.98 11.97 9 32492 62220 53254345
Oral discomfort 15.97 11.97 23 32478 8723 53307842
Dry mouth 15.77 11.97 75 32426 59475 53257090
Gastrointestinal motility disorder 15.57 11.97 17 32484 4879 53311686
Urine odour abnormal 15.49 11.97 18 32483 5528 53311037
Pain 15.44 11.97 468 32033 587930 52728635
Vomiting 15.37 11.97 212 32289 496927 52819638
Procedural pain 15.21 11.97 30 32471 14687 53301878
Ascites 14.95 11.97 3 32498 39732 53276833
Noninfectious myelitis 14.82 11.97 3 32498 10 53316555
Pleural rub 14.82 11.97 4 32497 56 53316509
Dyspnoea 14.75 11.97 260 32241 585972 52730593
Oesophagitis ulcerative 14.72 11.97 7 32494 534 53316031
Disease progression 14.37 11.97 25 32476 101895 53214670
Decreased appetite 14.21 11.97 75 32426 214899 53101666
Threatened labour 14.13 11.97 8 32493 875 53315690
Mastoiditis 13.86 11.97 8 32493 908 53315657
Hyperkalaemia 13.71 11.97 8 32493 54248 53262317
Hypoventilation 13.66 11.97 15 32486 4334 53312231
Bone hypertrophy 13.64 11.97 6 32495 382 53316183
Abdominal discomfort 13.58 11.97 79 32422 220983 53095582
Accidental overdose 13.53 11.97 36 32465 21443 53295122
Renal failure 13.37 11.97 33 32468 118419 53198146
Substance abuse 13.25 11.97 15 32486 4479 53312086
Anxiety 13.12 11.97 180 32321 196524 53120041
Platelet count decreased 13.09 11.97 29 32472 108070 53208495
Stomatitis 13.02 11.97 25 32476 98133 53218432
Yawning 12.91 11.97 8 32493 1033 53315532
Electrocardiogram PR prolongation 12.84 11.97 7 32494 712 53315853
Sinusitis 12.77 11.97 56 32445 168508 53148057
Acute lung injury 12.71 11.97 9 32492 1452 53315113
Radicular pain 12.59 11.97 6 32495 460 53316105
Extrapyramidal disorder 12.48 11.97 25 32476 12377 53304188
Spinal osteoarthritis 12.30 11.97 28 32473 15129 53301436
Multiple sclerosis relapse 12.25 11.97 57 32444 44796 53271769
Bundle branch block left 12.16 11.97 18 32483 6995 53309570
Anticonvulsant drug level above therapeutic 12.11 11.97 6 32495 501 53316064
White blood cell analysis abnormal 12.04 11.97 3 32498 30 53316535
Drug withdrawal syndrome 12.00 11.97 41 32460 27981 53288584

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 302.45 14.82 326 10105 177715 32325380
Completed suicide 214.57 14.82 201 10230 92316 32410779
Sedation 123.86 14.82 76 10355 18450 32484645
Suicidal ideation 90.41 14.82 84 10347 37999 32465096
Myokymia 84.77 14.82 16 10415 76 32503019
Electrocardiogram QRS complex prolonged 50.24 14.82 26 10405 4548 32498547
Brugada syndrome 47.74 14.82 15 10416 710 32502385
Nightmare 39.10 14.82 33 10398 13133 32489962
Nephrolithiasis 39.05 14.82 46 10385 27308 32475787
Drug abuse 38.90 14.82 82 10349 80161 32422934
Depression 36.83 14.82 90 10341 96970 32406125
Overdose 34.37 14.82 82 10349 86995 32416100
Respiratory depression 31.04 14.82 29 10402 13182 32489913
Serotonin syndrome 28.70 14.82 33 10398 19084 32484011
Drug abuser 27.51 14.82 17 10414 4167 32498928
Hyperhidrosis 25.92 14.82 65 10366 71103 32431992
Impaired quality of life 24.73 14.82 13 10418 2347 32500748
Fall 22.52 14.82 123 10308 196078 32307017
Inadequate analgesia 22.38 14.82 13 10418 2850 32500245
Reversible airways obstruction 22.10 14.82 7 10424 340 32502755
Major depression 21.65 14.82 15 10416 4456 32498639
Drug hypersensitivity 21.64 14.82 62 10369 73338 32429757
Substance abuse 21.48 14.82 18 10413 7089 32496006
Ventricular arrhythmia 19.94 14.82 15 10416 5064 32498031
Poisoning 19.75 14.82 21 10410 11137 32491958
Vertigo 19.63 14.82 31 10400 24252 32478843
Suspected suicide 19.14 14.82 12 10419 3016 32500079
Pyrexia 19.09 14.82 47 10384 319921 32183174
Somnolence 18.47 14.82 74 10357 103723 32399372
Anaemia 18.45 14.82 27 10404 223597 32279498
Contusion 18.32 14.82 36 10395 33432 32469663
Myoclonus 18.27 14.82 23 10408 14606 32488489
Febrile neutropenia 17.86 14.82 8 10423 119558 32383537
Binocular eye movement disorder 17.86 14.82 4 10427 49 32503046
Muscle spasms 17.48 14.82 56 10375 70362 32432733
Joint effusion 17.39 14.82 13 10418 4346 32498749
Suicide attempt 17.26 14.82 38 10393 38206 32464889
Action tremor 17.05 14.82 4 10427 61 32503034
Diarrhoea 16.44 14.82 61 10370 364741 32138354
Obsessive-compulsive disorder 15.96 14.82 13 10418 4921 32498174
Cervicogenic headache 15.60 14.82 3 10428 16 32503079
Myasthenia gravis crisis 15.44 14.82 6 10425 534 32502561
Tinnitus 15.32 14.82 23 10408 17226 32485869
Cardio-respiratory arrest 15.26 14.82 46 10385 55943 32447152
Dermatitis contact 15.24 14.82 11 10420 3487 32499608

Pharmacologic Action:

SourceCodeDescription
ATC N06AA10 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:35469 thymoanaleptics
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:68495 Type I programmed cell-death inducer
CHEBI has role CHEBI:176497 anti-aging drugs
FDA EPC N0000175752 Tricyclic Antidepressant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Neuropathic pain off-label use 247398009
Smoking cessation assistance off-label use 384742004
Attention deficit hyperactivity disorder off-label use 406506008
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Sinus tachycardia contraindication 11092001
Lowered convulsive threshold contraindication 19260006
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Renal failure syndrome contraindication 42399005 DOID:1074
Conduction disorder of the heart contraindication 44808001
Hepatic failure contraindication 59927004
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Bipolar affective disorder, current episode manic contraindication 191618007
Cerebrovascular accident contraindication 230690007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Non-Q wave myocardial infarction contraindication 314207007
Breastfeeding (mother) contraindication 413712001
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.34 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 8.36 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.56 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.51 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 7.36 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.07 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 8 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.67 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.26 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 7.22 DRUG MATRIX
Histamine H1 receptor GPCR Kd 8.03 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.64 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.40 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 6.96 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.30 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 7.08 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.01 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 6.07 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.52 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.92 PDSP
Cytochrome P450 2D6 Enzyme Km 6.23 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.91 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.52 DRUG MATRIX
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase IC50 5.82 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.57 DRUG MATRIX
ATP-sensitive inward rectifier potassium channel 10 Ion channel BLOCKER IC50 4.80 SCIENTIFIC LITERATURE
D(2) dopamine receptor GPCR Ki 5.59 PDSP
Alpha-1B adrenergic receptor GPCR Ki 6.94 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.84 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 10.40 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.73 CHEMBL
Histamine H1 receptor GPCR IC50 10.30 CHEMBL

External reference:

IDSource
4019860 VUID
N0000147946 NUI
D00816 KEGG_DRUG
894-71-3 SECONDARY_CAS_RN
4017520 VANDF
4019860 VANDF
C0028420 UMLSCUI
CHEBI:7640 CHEBI
21B PDB_CHEM_ID
CHEMBL445 ChEMBL_ID
DB00540 DRUGBANK_ID
CHEMBL1201156 ChEMBL_ID
D009661 MESH_DESCRIPTOR_UI
4543 PUBCHEM_CID
2404 IUPHAR_LIGAND_ID
1328 INN_ID
BL03SY4LXB UNII
203130 RXNORM
2733 MMSL
2740 MMSL
5192 MMSL
d00144 MMSL
001502 NDDF
004601 NDDF
13432000 SNOMEDCT_US
29666006 SNOMEDCT_US
372652004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0810 CAPSULE 10 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0811 CAPSULE 25 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0812 CAPSULE 50 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0813 CAPSULE 75 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0678 SOLUTION 10 mg ORAL ANDA 19 sections
PAMELOR HUMAN PRESCRIPTION DRUG LABEL 1 0406-9910 CAPSULE 10 mg ORAL NDA 19 sections
PAMELOR HUMAN PRESCRIPTION DRUG LABEL 1 0406-9911 CAPSULE 25 mg ORAL NDA 19 sections
PAMELOR HUMAN PRESCRIPTION DRUG LABEL 1 0406-9912 CAPSULE 50 mg ORAL NDA 19 sections
PAMELOR HUMAN PRESCRIPTION DRUG LABEL 1 0406-9913 CAPSULE 75 mg ORAL NDA 19 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-567 CAPSULE 10 mg ORAL ANDA 18 sections
NORTRIPTYLINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-171 CAPSULE 25 mg ORAL ANDA 16 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-093 CAPSULE 10 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-094 CAPSULE 25 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-599 CAPSULE 50 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-600 CAPSULE 75 mg ORAL ANDA 13 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-348 CAPSULE 25 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-532 CAPSULE 10 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-692 CAPSULE 50 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-804 CAPSULE 75 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-722 CAPSULE 25 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-897 CAPSULE 25 mg ORAL ANDA 19 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 45865-371 CAPSULE 10 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0507 CAPSULE 25 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0537 CAPSULE 10 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1323 CAPSULE 50 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-603 CAPSULE 10 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-604 CAPSULE 25 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-605 CAPSULE 50 mg ORAL ANDA 18 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50436-4022 CAPSULE 25 mg ORAL ANDA 17 sections
Nortriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50436-6652 CAPSULE 10 mg ORAL ANDA 18 sections